CUE News and Press, Cue Biopharma Inc. From 11/09/23

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, provided a business and financial update for the third quarter of 2023. R...

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of T cell engagers to selectively modulate tumor-specific T cells, announced today that it will participate in three investor conferences this Novem...

Overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first line (1L) recurrent/metastatic HNSCC patients treated with CUE-101 and KEYTRUDA ® (pembrolizumab) ORR of 56% in patients with low expression of PD-L1 in the tumor Median overall survival...

BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today two ...

Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA ® (pembrolizumab) in first line (1L) refractory/metastatic HPV+ Head and Neck Cancer patients Data to date from CUE-101 in combination with pembrolizumab demo...

2023-08-10 18:02:10 ET Summary Cue Biopharma published phase 1 data for lead candidate CUE-101, showing clinical activity and favorable tolerability in patients with HPV-positive head and neck squamous cell carcinoma. The company also presented data from a phase 1b trial combining...

2023-08-09 22:23:03 ET Cue Biopharma, Inc. (CUE) Q2 2023 Earnings Conference Call August 09, 2023 04:30 PM ET Company Participants Dan Passeri - Chief Executive Officer Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer...

2023-08-09 16:50:27 ET Cue Biopharma press release ( NASDAQ: CUE ): Q2 GAAP EPS of -$0.29 beats by $0.01 . Revenue of $1.38M (+430.8% Y/Y) beats by $0.47M . For further details see: Cue Biopharma GAAP EPS of -$0.29 beats by $0.01, revenue of $1.38M beats ...

BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business a...

2023-07-12 08:24:50 ET Ault Alliance ( NYSE: AULT ) +152% . Healthcare Triangle ( HCTI ) +127% . Cadrenal Therapeutics ( CVKD ) +61% . Liminal BioSciences  ( LMNL ) +40% to go private in buyout deal with Structured Alpha. BitNil...